Who is affected by this change?

This affects Independence Blue Cross Oncology, Hematology providers on Medicare Advantage plans.

When does this change take effect?

This change is effective Jan 1, 2026.

Back to dashboard

Medicare AdvantageCoverageMedium impact

MA08.085k, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)

Independence Blue Cross·Oncology, Hematology·Pharmacy

Effective date

Jan 1, 2026

We identified it

Jun 19, 2026

Days to comply

—

Summary

Medicare Advantage policy MA08.085k has been updated for Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®), a specialty pharmacy medication. This policy change affects coverage or billing requirements for this specific cancer treatment drug effective January 1, 2026.

Action Required

Action needed

Before January 1, 2026: Billing team must review the complete policy MA08.085k for Rylaze® to understand updated coverage criteria, prior authorization requirements, and billing procedures. Access the full policy at the provided URL to determine specific billing code changes and documentation requirements for this specialty oncology medication.

Related policy hubs

Independence Blue Cross policies Oncology Hematology